Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00320671 · ClinicalTrials.gov registry record · Phase 4
Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
A Phase 4 study of Schizophrenia, sponsored by Northwell Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 198
- Enrollment target
- 1
- Study location
NCT00320671 is a Phase 4 study of Schizophrenia that has completed, run by Northwell Health. The registered enrollment target is 198 participants, roughly in line with the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT00320671, a Phase 4 study of Schizophrenia, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 198 participants
- Enrollment target
- 1
- Study location
Study Summary
This 52 week long study evaluates the effectiveness of aripiprazole versus risperidone in treating people with first-episode schizophrenia. Patients who do not improve with these medications receive clozapine as their third medication trial.
Conditions Studied
Interventions
- DRUG Risperidone
- DRUG Aripiprazole
Study Locations (1)
New York
- The Zucker Hillside Hospital - Glen Oaks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2005-12 |
| Est. Completion | 2015-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00320671
The ClinicalTrials.gov registry entry for NCT00320671 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Risperidone is the first listed.
NCT00320671 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00320671 about?
NCT00320671 is a clinical study titled "Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis". This 52 week long study evaluates the effectiveness of aripiprazole versus risperidone in treating people with first-episode schizophrenia. Patients who do not improve with these medications receive clozapine as their third medication trial.
What is the current status of trial NCT00320671?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 198 participants. The study started on 2005-12. Estimated completion is 2015-12.
What conditions does trial NCT00320671 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00320671?
The interventions under investigation include: Risperidone (DRUG), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00320671?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00320671 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.